PMID- 28027771
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20220321
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 86
DP  - 2017 Jan
TI  - Dynamic contrast-enhanced perfusion area-detector CT assessed with various 
      mathematical models: Its capability for therapeutic outcome prediction for 
      non-small cell lung cancer patients with chemoradiotherapy as compared with that 
      of FDG-PET/CT.
PG  - 83-91
LID - S0720-048X(16)30356-4 [pii]
LID - 10.1016/j.ejrad.2016.11.008 [doi]
AB  - PURPOSE: To directly compare the capability of dynamic first-pass 
      contrast-enhanced (CE-) perfusion area-detector CT (ADCT) and PET/CT for early 
      prediction of treatment response, disease progression and overall survival of 
      non-small cell carcinoma (NSCLC) patients treated with chemoradiotherapy. 
      MATERIALS AND METHODS: Fifty-three consecutive Stage IIIB NSCLC patients who had 
      undergone PET/CT, dynamic first-pass CE-perfusion ADCT, chemoradiotherapy, and 
      follow-up examination were enrolled in this study. They were divided into two 
      groups: 1) complete or partial response (CR+PR) and 2) stable or progressive 
      disease (SD+PD). Pulmonary arterial and systemic arterial perfusions and total 
      perfusion were assessed at targeted lesions with the dual-input maximum slope 
      method, permeability surface and distribution volume with the Patlak plot method, 
      tumor perfusion with the single-input maximum slope method, and SUV(max), and 
      results were averaged to determine final values for each patient. Next, step-wise 
      regression analysis was used to determine which indices were the most useful for 
      predicting therapeutic effect. Finally, overall survival of responders and 
      non-responders assessed by using the indices that had a significant effect on 
      prediction of therapeutic outcome was statistically compared. RESULTS: The 
      step-wise regression test showed that therapeutic effect (r(2)=0.63, p=0.01) was 
      significantly affected by the following three factors in order of magnitude of 
      impact: systemic arterial perfusion, total perfusion, and SUV(max). Mean overall 
      survival showed a significant difference for total perfusion (p=0.003) and 
      systemic arterial perfusion (p=0.04). CONCLUSION: Dynamic first-pass CE-perfusion 
      ADCT as well as PET/CT are useful for treatment response prediction in NSCLC 
      patients treated with chemoradiotherapy.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Ohno, Yoshiharu
AU  - Ohno Y
AD  - Division of Functional and Diagnostic Imaging Research, Department of Radiology, 
      Kobe University Graduate School of Medicine, Kobe, Japan; Advanced Biomedical 
      Imaging Research Center, Kobe University Graduate School of Medicine, Kobe, 
      Japan. Electronic address: yosirad@kobe-u.ac.jp.
FAU - Fujisawa, Yasuko
AU  - Fujisawa Y
AD  - Toshiba Medical Systems Corporation, Otawara, Japan.
FAU - Koyama, Hisanobu
AU  - Koyama H
AD  - Division of Radiology, Department of Radiology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
FAU - Kishida, Yuji
AU  - Kishida Y
AD  - Division of Radiology, Department of Radiology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
FAU - Seki, Shinichiro
AU  - Seki S
AD  - Division of Radiology, Department of Radiology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
FAU - Sugihara, Naoki
AU  - Sugihara N
AD  - Toshiba Medical Systems Corporation, Otawara, Japan.
FAU - Yoshikawa, Takeshi
AU  - Yoshikawa T
AD  - Division of Functional and Diagnostic Imaging Research, Department of Radiology, 
      Kobe University Graduate School of Medicine, Kobe, Japan; Advanced Biomedical 
      Imaging Research Center, Kobe University Graduate School of Medicine, Kobe, 
      Japan.
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
DEP - 20161106
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*therapy
MH  - Chemoradiotherapy/*methods
MH  - Disease-Free Survival
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Lung Neoplasms/diagnostic imaging/*therapy
MH  - Male
MH  - Middle Aged
MH  - Models, Theoretical
MH  - Multimodal Imaging/methods
MH  - Positron Emission Tomography Computed Tomography
MH  - Prognosis
MH  - Prospective Studies
MH  - Radiopharmaceuticals
MH  - Tomography, Spiral Computed/methods
MH  - Tomography, X-Ray Computed/methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CT
OT  - Non-small cell lung cancer
OT  - PET/CT
OT  - Perfusion
OT  - Therapeutic effect
EDAT- 2016/12/29 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/12/29 06:00
PHST- 2016/10/10 00:00 [received]
PHST- 2016/11/02 00:00 [revised]
PHST- 2016/11/03 00:00 [accepted]
PHST- 2016/12/29 06:00 [entrez]
PHST- 2016/12/29 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S0720-048X(16)30356-4 [pii]
AID - 10.1016/j.ejrad.2016.11.008 [doi]
PST - ppublish
SO  - Eur J Radiol. 2017 Jan;86:83-91. doi: 10.1016/j.ejrad.2016.11.008. Epub 2016 Nov 
      6.